It’s the stuff investors’ dreams are made of: Near 100% gains in about a month…

Except if you’re a Palm Beach Confidential subscriber, those gains are yours to keep.

On Monday, drugmaker Sarepta Therapeutics Inc. (SRPT) received Food and Drug Administration (FDA) approval for eteplirsen (a Duchenne muscular dystrophy drug). The stock rocketed up over 90% in a few hours.

Chart

Here’s what Teeka told Palm Beach Confidential subscribers about the move…

From Teeka Tiwari, editor, Palm Beach Confidential: We first recommended the company in our August special report, “FDA Loophole: This Secret FDA Signal Could Double Your Money in Days.”

In that report, I showed you what could happen when a company has an important drug approved… They see considerable stock-price appreciation.

In my original write-up, I told you a decision on eteplirsen could be made as early as late August.

Then just last week, I told you that one of the FDA’s most prominent critics of eteplirsen had just left the agency. “With this hurdle out of the way, I expect we’ll see an approval and a voucher in the next few weeks,” I said.

That’s exactly what happened.

Since receiving FDA approval, the stock shot up more than 100% above our original recommended price.

If you haven’t already, take profits and sell your shares of Sarepta Therapeutics (SRPT). And as always… let the game come to you!

Reeves’ Note: The report Teeka mentioned above contains a “hotlist” of seven other biotechnology firms poised to enjoy similar moves. It’s all thanks to a special FDA “loophole” in their extensive drug-approval process. Current Confidential subscribers can click here to read it.